SIL index, comprising stage, soluble interleukin‐2 receptor, and lactate dehydrogenase, is a useful prognostic predictor in diffuse large B‐cell lymphoma

Rituximab (R) plus doxorubicin, cyclophosphamide, vincristine, and prednisolone (CHOP) chemotherapy (R‐CHOP) is widely accepted as standard care for diffuse large B‐cell lymphoma (DLBCL) patients. The revised International Prognostic Index (R‐IPI) was established in 2007 after the addition of rituxi...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancer Sci
Главные авторы: Tomita, Naoto, Sakai, Rika, Fujisawa, Shin, Fujimaki, Katsumichi, Taguchi, Jun, Hashimoto, Chizuko, Ogawa, Koji, Yamazaki, Etsuko, Ishigatsubo, Yoshiaki
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2012
Предметы:
Original Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7659199/
https://ncbi.nlm.nih.gov/pubmed/22587388
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1349-7006.2012.02331.x
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы